Skip to content
About Prolight
Market
Partnerships
Board of Directors and Management
Clinical Advisory Board
History
Cutting-edge technology
Vision & strategy
Products
Psyros™
MicroFlex
Patents
Investors
Press releases
Financial reports
CEO comment
Financial calendar
Stock information
AGM
Shareholders
Key figures
Corporate governance
Prospectus
Media
Press releases
Investor letters
Media gallery
Presentations
Articles
Contact us
Menu
About Prolight
Market
Partnerships
Board of Directors and Management
Clinical Advisory Board
History
Cutting-edge technology
Vision & strategy
Products
Psyros™
MicroFlex
Patents
Investors
Press releases
Financial reports
CEO comment
Financial calendar
Stock information
AGM
Shareholders
Key figures
Corporate governance
Prospectus
Media
Press releases
Investor letters
Media gallery
Presentations
Articles
Contact us
EN
SV
Articles
2024
Prolight’s partner TTP provides update on MicroFlex development (BioStock)
Prolight Diagnostics strengthens board with experienced business developer (BioStock)
Prolight Diagnostics CSO comments on latest data (BioStock)
Prolight Diagnostics’ CTO thrilled to receive UK government grant (BioStock)
PROLIGHT: SEK 17m UK grant a welcome external validation (Emergers)
Prolight Diagnostics selects partner to conduct clinical validation studies (BioStock)
Prolight Diagnostics finalises cartridge design (BioStock)
Bra slagläge för hjärtbiomarkörtest (Mangold) (Swedish)
PROLIGHT: Important milestone amidst mixed news flow (Emergers)
Prolight Diagnostics’ collaboration with G&H | ITL propels development (BioStock)
Prolight’s COO comments on partnership with FlexMedical Solutions (BioStock)
Prolight Diagnostics’ CTO highlights the potential of the Psyros system (BioStock)
Prolight Diagnostics CEO: “We deliver on all goals” (BioStock)
Prolight: Single molecule biomarker POC test upcoming (Emergers)
Prolight‘s CEO: “Roche’s acquisition highlights interest in Point-of-Care”
2023
Prolight Diagnostics’ CEO comments on the outcome of the rights issue (BioStock)
Emission ska ta Prolight Diagnostics patientnära analyssystem till marknad (BioStock)
Prolight Diagnostics vd: ”Vi accelererar mot lansering” (BioStock)
Banbrytande teknik upptäcker och utesluter hjärtinfart (SvD)
Prolight’s CEO: ”Proof-of-Performance in whole blood important milestone” (BioStock) - English
Interview with Prolight Diagnostics CEO Ulf Bladin (Merger Market)
Prolight Diagnostics lanserar ny hemsida i samband med internationell kongress (Finwire)
Prolight Diagnostics ska visa upp POC-system vid AACC-kongress (Finwire)
Prolight Diagnostics-bolaget Psyros visar proof-of-performance för hjärtinfarkttest (Finwire)
Betydelsefulla patentansökningar från Prolight Diagnostics - vd (Finwire)
2022 (Only in Swedish)
BioStock: Prolight Diagnostics angående fokusområden för 2022
BioStock: Emission och förvärv öppnar dörrar för Prolight Diagnostics
Native ads
2022 (Only in Swedish)
Svenska Prolight Diagnostics kan bli ett helt unikt bolag inom patientnära testsystem – DN Innovation
Prolight Diagnostics kan bli ett unikt bolag inom patientnära testsystem, IR-intervju -Dagens industri
Prolight Diagnostics förvärvar brittiskt bolag för att ta en ledande position inom patientnära diagnostik -BioStock
Banbrytande testsystem kan revolutionera klinisk diagnostisering -Affärsvärlden
Kan vara början på ett paradigmskifte inom POC -Aktiespararna
Prolight Diagnostics kan bli ett helt unikt bolag inom patientnära testsystem – Realtid
